CELU

Celularity Class A (CELU)

About Celularity Class A (CELU)

Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert Joseph Hariri Gordon in 2016 and is headquartered in Florham Park, NJ.

Details

Daily high
$2.64
Daily low
$2.40
Price at open
$2.55
52 Week High
$7.97
52 Week Low
$1.59
Market cap
55.6M
Dividend yield
0.00%
Volume
37,186
Avg. volume
18,783
P/E ratio
-.22

Celularity Class A News

Details

Daily high
$2.64
Daily low
$2.40
Price at open
$2.55
52 Week High
$7.97
52 Week Low
$1.59
Market cap
55.6M
Dividend yield
0.00%
Volume
37,186
Avg. volume
18,783
P/E ratio
-.22